Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Researchers conducted the ECHELON-2 trial to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

Researchers conducted the ECHELON-2 trial to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas. For the study, 452 adults from 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas were randomly assigned to receive either A+CHP or CHOP for six or eight 21-day cycles. Median progression-free survival—the primary endpoint—was 48.2 months in the A+CHP group and 20.8 months in the CHOP group. The groups saw similar adverse events, including the incidence and severity of febrile neutropenia and peripheral neuropathy. In all, seven patients (3%) in the A+CHP group and nine (4%) in the CHOP group suffered fatal adverse events. According to the authors, the findings indicate "that the addition of brentuximab vedotin to CHP resulted in higher rates of progression-free and overall survival without added toxicity and supports the potential for A+CHP to become a new standard of care for many patients with CD30-positive peripheral T-cell lymphoma."